Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) insider Fmr Llc sold 53,454 shares of the business's stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the completion of the sale, the insider directly owned 2,056,081 shares of the company's stock, valued at $62,114,207.01. This represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Fmr Llc also recently made the following trade(s):
- On Monday, November 9th, Fmr Llc sold 175,000 shares of Avalyn Pharma stock. The stock was sold at an average price of $29.07, for a total transaction of $5,087,250.00.
Avalyn Pharma Stock Down 3.3%
Shares of NASDAQ:AVLN opened at $30.59 on Friday. Avalyn Pharma Inc. has a 12-month low of $22.24 and a 12-month high of $40.17. The stock's 50 day simple moving average is $28.77. The firm has a market cap of $1.36 billion and a price-to-earnings ratio of -1.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12.
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.03). On average, research analysts expect that Avalyn Pharma Inc. will post -3.86 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on the company. Wall Street Zen lowered Avalyn Pharma from a "hold" rating to a "sell" rating in a research note on Sunday, September 20th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Avalyn Pharma in a research report on Wednesday. Morgan Stanley increased their target price on Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Finally, Raymond James Financial began coverage on Avalyn Pharma in a report on Friday, October 2nd. They set an "outperform" rating and a $60.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $60.00.
Check Out Our Latest Stock Analysis on Avalyn Pharma
Hedge Funds Weigh In On Avalyn Pharma
Several hedge funds and other institutional investors have recently made changes to their positions in AVLN. State Street Corp lifted its holdings in shares of Avalyn Pharma by 73.7% during the 3rd quarter. State Street Corp now owns 554,004 shares of the company's stock worth $15,784,000 after acquiring an additional 235,009 shares during the period. Profund Advisors LLC acquired a new stake in shares of Avalyn Pharma during the 3rd quarter worth approximately $668,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Avalyn Pharma during the 3rd quarter worth approximately $29,000. Manchester Capital Management LLC acquired a new stake in shares of Avalyn Pharma during the 3rd quarter worth approximately $36,000. Finally, Braidwell LP bought a new position in Avalyn Pharma in the second quarter valued at approximately $26,382,000.
Avalyn Pharma Company Profile
(
Get Free Report)
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
